An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Puddu, Alessandra ^a   MacH, François ^b   Nencioni, Alessio ^a   Viviani, Giorgio Luciano ^a   Montecucco, Fabrizio ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCOGEN SYNTHASE; INSULIN; TRANSCRIPTION FACTOR PDX 1;

ADIPOCYTE; ANTIOXIDANT ACTIVITY; CELL DEATH; CELL STRESS; ENZYME ACTIVITY; FOOD INTAKE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SYNTHESIS; L CELL; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SATIETY; STOMACH EMPTYING; ARTICLE; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; SIGNAL TRANSDUCTION;

EID: 84873403513     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/591056     Document Type: Review

References (96)

1. Holst J. J., The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 4 1409 1439 2-s2.0-35748957503 10.1152/physrev.00034.2006 (Pubitemid 350041474)
2. Garber A. J., Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care 2011 34 supplement 2 S258 S263 2-s2.0-79959803070
3. Ross S. A., Ekoé J. M., Incretin agents in type 2 diabetes. Canadian Family Physician 2010 56 7 639 648 2-s2.0-77956581914
4. Drucker D. J., Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 9548 1696 1705 2-s2.0-33846006173 10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
5. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands J. L., Smit A., The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovascular Diabetology 2008 7, article no. 29 2-s2.0-54349093815 10.1186/1475-2840-7-29
6. Singh R., Barden A., Mori T., Beilin L., Advanced glycation end-products: A review. Diabetologia 2001 44 2 129 146 2-s2.0-0035135246 10.1007/ s001250051591 (Pubitemid 32156196)
7. Yan S. F., Ramasamy R., Schmidt A. M., The RAGE axis a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation Research 2010 106 5 842 853 2-s2.0-77950898257 10.1161/CIRCRESAHA.109.212217
8. Lund P. K., Goodman R. H., Habener J. F., Intestinal glucagon mRNA identified by hybridization to a cloned islet cDNA encoding a precursor. Biochemical and Biophysical Research Communications 1981 100 4 1659 1666 2-s2.0-0019576004
9. Lund P. K., Goodman R. H., Dee P. C., Habener J. F., Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proceedings of the National Academy of Sciences of the United States of America 1982 79 2 I 345 349 2-s2.0-0020026919 (Pubitemid 12137713)
10. Lund P. K., Goodman R. H., Montminy M. R., Anglerfish islet pre-proglucagon II: Nucleotide and corresponding amino acid sequence of the cDNA. Journal of Biological Chemistry 1983 258 5 3280 3284 2-s2.0-0020534249 (Pubitemid 13130241)
11. Kieffer T. J., Habener J. F., The glucagon-like peptides. Endocrine Reviews 1999 20 6 876 913 2-s2.0-0033304603 (Pubitemid 30647076)
12. Ugleholdt R., Zhu X., Deacon C. F., Ørskov C., Steiner D. F., Holst J. J., Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1. Endocrinology 2004 145 3 1349 1355 2-s2.0-1442274636 10.1210/en.2003-0801 (Pubitemid 38281019)
13. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J. J., Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994 43 4 535 539 2-s2.0-0028281773 (Pubitemid 24096293)
14. Orskov C., Wettergren A., Holst J. J., Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993 42 5 658 661 2-s2.0-0027157849 (Pubitemid 23127154)
15. Martinez A., Burrell M. A., Kuijk M., Montuenga L. M., Treston A., Cuttitta F., Polak J. M., Localization of amidating enzymes (PAM) in rat gastrointestinal tract. Journal of Histochemistry and Cytochemistry 1993 41 11 1617 1622 2-s2.0-0027482849 (Pubitemid 23317106)
16. Deacon C. F., Nauck M. A., Toft-Nielsen M., Pridal L., Willms B., Holst J. J., Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995 44 9 1126 1131 2-s2.0-0028803336
17. Lambeir A. M., Durinx C., Scharpé S., De Meester I., Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences 2003 40 3 209 294 2-s2.0-0037787851 (Pubitemid 36775376)
18. Herrmann C., Goke R., Richter G., Fehmann H. C., Arnold R., Goke B., Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients. Digestion 1995 56 2 117 126 2-s2.0-0028838030
19. Elliott R. M., Morgan L. M., Tredger J. A., Deacon S., Wright J., Marks V., Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. Journal of Endocrinology 1993 138 1 159 166 2-s2.0-0027227370 (Pubitemid 23266831)
20. Rask E., Olsson T., Söderberg S., Johnson O., Seckl J., Holst J. J., Ahrén B., Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001 24 9 1640 1645 2-s2.0-0035462466 (Pubitemid 33716463)
21. Drucker D. J., Philippe J., Mojsov S., Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proceedings of the National Academy of Sciences of the United States of America 1987 84 10 3434 3438 2-s2.0-0344357096 (Pubitemid 17085418)
22. Holst J. J., Orskov C., Nielsen O. V., Schwartz T. W., Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Letters 1987 211 2 169 174 2-s2.0-0023104829 (Pubitemid 17049446)
23. Kreymann B., Williams G., Ghatei M. A., Bloom S. R., Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987 2 8571 1300 1304 2-s2.0-0023638829 (Pubitemid 17156636)
24. Mojsov S., Weir G. C., Habener J. F., Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation 1987 79 2 616 619 2-s2.0-0023107555 (Pubitemid 17009701)
25. Drucker D. J., Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Current Pharmaceutical Design 2001 7 14 1399 1412 2-s2.0-0034857141 10.2174/ 1381612013397401 (Pubitemid 32798817)
26. Drucker D. J., Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002 122 2 531 544 2-s2.0-0036158954 (Pubitemid 34117003)
27. Thorens B., Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America 1992 89 18 8641 8645 2-s2.0-0026775150
28. Drucker D. J., Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 10 2929 2940 2-s2.0-0141446228 10.2337/diacare.26.10.2929 (Pubitemid 37205571)
29. Farilla L., Bulotta A., Hirshberg B., Li Calzi S., Khoury N., Noushmehr H., Bertolotto C., Di Mario U., Harlan D. M., Perfetti R., Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003 144 12 5149 5158 2-s2.0-0345374580 10.1210/en.2003-0323 (Pubitemid 37476040)
30. MacDonald P. E., El-kholy W., Riedel M. J., Salapatek A. M. F., Light P. E., Wheeler M. B., The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002 51 supplement 3 S434 S442 2-s2.0-0036894315 (Pubitemid 35403427)
31. Xu G., Stoffers D. A., Habener J. F., Bonner-Weir S., Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999 48 12 2270 2276 2-s2.0-0033513455 (Pubitemid 30395416)
32. Gutzwiller J. P., Göke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., Beglinger C., Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999 44 1 81 86 2-s2.0-0002300343 (Pubitemid 29143284)
33. Delgado-Aros S., Kim D. Y., Burton D. D., Thomforde G. M., Stephens D., Brinkmann B. H., Vella A., Camilleri M., Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. American Journal of Physiology 2002 282 3 G424 G431 2-s2.0-0036086315 (Pubitemid 34651657)
34. Meier J. J., Gallwitz B., Schmidt W. E., Nauck M. A., Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives. European Journal of Pharmacology 2002 440 2-3 269 279 2-s2.0-0037066595 10.1016/S0014-2999(02)01434-6 (Pubitemid 34460704)
35. Egan J. M., Montrose-Rafizadeh C., Wang Y., Bernier M., Roth J., Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action. Endocrinology 1994 135 5 2070 2075 2-s2.0-0028077525 10.1210/en.135.5.2070 (Pubitemid 24363904)
36. Luque M. A., González N., Márquez L., Acitores A., Redondo A., Morales M., Valverde I., Villanueva-Peñacarrillo M. L., Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. Journal of Endocrinology 2002 173 3 465 473 2-s2.0-0036305993 10.1677/joe.0.1730465 (Pubitemid 34704718)
37. Perea A., Viñambres C., Clemente F., Villanueva-Peñacarrillo M. L., Valverde I., GLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue. Hormone and Metabolic Research 1997 29 9 417 421 2-s2.0-0030722287
38. Abu-Hamdah R., Rabiee A., Meneilly G. S., Shannon R. P., Andersen D. K., Elahi D., The extrapancreatic effects of glucagon-like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009 94 6 1843 1852 2-s2.0-66749102158 10.1210/jc.2008-1296
39. Holscher C., Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012 26 10 871 882 10.2165/11635890-000000000-00000
40. Vollmer K., Hoist J. J., Bailer B., Ellrlchmann M., Nauck M. A., Schmidt W. E., Meier J. J., Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008 57 3 678 687 2-s2.0-40949090627 10.2337/db07-1124
41. Nauck M., Stockmann F., Ebert R., Creutzfeldt W., Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 1 46 52 2-s2.0-0022617246 (Pubitemid 16162741)
42. Toft-Nielsen M. B., Damholt M. B., Madsbad S., Hilsted L. M., Hughes T. E., Michelsen B. K., Holst J. J., Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2001 86 8 3717 3723 2-s2.0-0034880655 10.1210/jc.86.8.3717 (Pubitemid 32755966)
43. Vilsbøll T., Krarup T., Deacon C. F., Madsbad S., Holst J. J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 3 609 613 2-s2.0-0001095690 (Pubitemid 32195226)
44. Nauck M. A., Heimesaat M. M., Orskov C., Holst J. J., Ebert R., Creutzfeldt W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 1993 91 1 301 307 2-s2.0-0027391607 (Pubitemid 23037285)
45. Elahi D., McAloon-Dyke M., Fukagawa N. K., Meneilly G. S., Sclater A. L., Minaker K. L., Habener J. F., Andersen D. K., The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 1994 51 1 63 74 2-s2.0-0028224617 10.1016/0167-0115(94)90136-8 (Pubitemid 24119981)
46. Willms B., Werner J., Holst J. J., Ørskov C., Creutzfeldt W., Nauck M. A., Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (Noninsulin-Dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 1996 81 1 327 332 2-s2.0-0030068620
47. Phillips L. K., Prins J. B., Update on incretin hormones. Annals of the New York Academy of Sciences 2011 1243 E55 E74 10.1111/j.1749-6632.2012.06491.x
48. Knop F. K., Vilsbøll T., Holst J. J., Incretin-based therapy of type 2 diabetes mellitus. Current Protein and Peptide Science 2009 10 1 46 55 2-s2.0-63849220179 10.2174/138920309787315158
49. Vilsbøll T., Knop F. K., Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. BioDrugs 2008 22 4 251 257 2-s2.0-47049124536 10.2165/00063030-200822040-00004 (Pubitemid 351969832)
50. Verspohl E. J., Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacology and Therapeutics 2009 124 1 113 138 2-s2.0-68949159829 10.1016/j.pharmthera.2009.06.002
51. Ahrén B., Landin-Olsson M., Jansson P. A., Svensson M., Holmes D., Schweizer A., Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89 5 2078 2084 2-s2.0-2442482515 10.1210/jc.2003-031907 (Pubitemid 38619835)
52. Fehmann H. C., Jiang J., Schweinfurth J., Wheeler M. B., Boyd A. E., Goke B., Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 1994 15 3 453 456 2-s2.0-0028358615 10.1016/0196-9781(94)90204-6
53. Herman G. A., Stevens C., Van Dyck K., Bergman A., Yi B., De Smet M., Snyder K., Hilliard D., Tanen M., Tanaka W., Wang A. Q., Zeng W., Musson D., Winchell G., Davies M. J., Ramael S., Gottesdiener K. M., Wagner J. A., Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology and Therapeutics 2005 78 6 675 688 2-s2.0-28844482322 10.1016/j.clpt.2005.09.002 (Pubitemid 41773643)
54. Goke R., Fehmann H. C., Linn T., Schmidt H., Krause M., Eng J., Goke B., Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β -cells. Journal of Biological Chemistry 1993 268 26 19650 19655 2-s2.0-0027184119 (Pubitemid 23270754)
55. Knudsen L. B., Nielsen P. F., Huusfeldt P. O., Johansen N. L., Madsen K., Pedersen F. Z., Thøgersen H., Wilken M., Agersø H., Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry 2000 43 9 1664 1669 2-s2.0-0034108646 10.1021/jm9909645 (Pubitemid 30304999)
56. Mari A., Sallas W. M., He Y. L., Watson C., Ligueros-Saylan M., Dunning B. E., Deacon C. F., Holst J. J., Foley J. E., Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β -cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005 90 8 4888 4894 2-s2.0-23844463766 10.1210/jc.2004-2460 (Pubitemid 41159387)
57. Tessier F. J., The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathologie Biologie 2010 58 3 214 219 2-s2.0-77953621114 10.1016/j.patbio.2009.09.014
58. Monnier V. M., Nonenzymatic glycosylation, the Maillard reaction and the aging process. Journals of Gerontology 1990 45 4 B105 B111 2-s2.0-0025373091 (Pubitemid 20224052)
59. Dyer D. G., Blackledge J. A., Katz B. M., Hull C. J., Adkisson H. D., Thorpe S. R., Lyons T. J., Baynes J. W., The Maillard reaction in vivo. Zeitschrift fur Ernahrungswissenschaft 1991 30 1 29 45 2-s2.0-0025978323
60. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., Lee A., Al-Abed Y., Vlassara H., Bucala R., Cerami A., Tobacco smoke is a source of toxic reactive glycation products. Proceedings of the National Academy of Sciences of the United States of America 1997 94 25 13915 13920 2-s2.0-13144252260 10.1073/pnas.94.25.13915 (Pubitemid 28009684)
61. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., Peppa M., Rayfield E. J., Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National Academy of Sciences of the United States of America 2002 99 24 15596 15601 2-s2.0-0037180567 10.1073/pnas.242407999 (Pubitemid 35403978)
62. Uribarri J., Cai W., Sandu O., Peppa M., Goldberg T., Vlassara H., Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Annals of the New York Academy of Sciences 2005 1043 461 466 2-s2.0-23744440311 10.1196/annals.1333.052 (Pubitemid 41123934)
63. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 6865 813 820 2-s2.0-0035856980 10.1038/414813a (Pubitemid 34000785)
64. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M., The biology of the receptor for advanced glycation end products and its ligands. Biochimica et Biophysica Acta 2000 1498 2-3 99 111 2-s2.0-0034695098 10.1016/S0167-4889(00) 00087-2
65. Vlassara H., The AGE-receptor in the pathogenesis of diabetic complications. Diabetes/Metabolism Research and Reviews 2001 17 6 436 443 2-s2.0-0035668462 10.1002/dmrr.233 (Pubitemid 34030746)
66. Ceriello A., The emerging challenge in diabetes: the 'metabolic memory'. Vascular Pharmacology 2012 57 5-6 133 138 10.1016/j.vph.2012.05.005
67. Ahmed N., Thornalley P. J., Advanced glycation endproducts: What is their relevance to diabetic complications? Diabetes, Obesity and Metabolism 2007 9 3 233 245 2-s2.0-33947671901 10.1111/j.1463-1326.2006.00595.x (Pubitemid 46502041)
68. Brownlee M., The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005 54 6 1615 1625 2-s2.0-20044376702 10.2337/diabetes.54. 6.1615 (Pubitemid 40770750)
69. Prasad A., Bekker P., Tsimikas S., Advanced glycation end products and diabetic cardiovascular disease. Cardiology in Review 2012 20 4 177 183 10.1097/CRD.0b013e318244e57c
70. Ramasamy R., Yan S. F., Schmidt A. M., Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences 2011 1243 88 102 10.1111/j.1749-6632.2011.06320.x
71. Zong H., Ward M., Stitt A. W., AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011 11 4 244 252 10.1007/s11892-011-0198-7
72. Puddu A., Storace D., Odetti P., Viviani G. L., Advanced glycation end-products affect transcription factors regulating insulin gene expression. Biochemical and biophysical research communications 2010 395 1 122 125 2-s2.0-77951905952 10.1016/j.bbrc.2010.03.152
73. Luciano Viviani G., Puddu A., Sacchi G., Garuti A., Storace D., Durante A., Monacelli F., Odetti P., Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro. Metabolism: Clinical and Experimental 2008 57 2 163 169 2-s2.0-38049144209 10.1016/j.metabol.2007.08.020
74. Lim M., Park L., Shin G., Hong H., Kang I., Park Y., Induction of apoptosis of β cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Annals of the New York Academy of Sciences 2008 1150 311 315 2-s2.0-57749184079 10.1196/annals.1447.011
75. Ge Q. M., Dong Y., Su Q., Effects of glucose and advanced glycation end products on oxidative stress in MIN6 cells. Cellular and Molecular Biology 2010 56 supplement 1 OL1231 OL1238 2-s2.0-77951892804 10.1170/140
76. Zhao Z., Zhao C., Xu H. Z., Zheng F., Cai W., Vlassara H., Ma Z. A., Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 2009 150 6 2569 2576 2-s2.0-66649125230 10.1210/en.2008-1342
77. Puddu A., Storace D., Durante A., Odetti P., Viviani G. L., Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Biochemical and Biophysical Research Communications 2010 398 3 462 466 2-s2.0-77955273235 10.1016/j.bbrc.2010.06.100
78. Minakawa M., Kawano A., Miura Y., Yagasaki K., Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β -cells. Journal of Clinical Biochemistry and Nutrition 2011 48 3 237 244 2-s2.0-79955441995 10.3164/jcbn.10-119
79. Dhar A., Dhar I., Jiang B., Desai K. M., Wu L., Chronic methylglyoxal infusion by minipump causes pancreatic β -cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 2011 60 3 899 908 2-s2.0-79952403213 10.2337/db10-0627
80. Zhu Y., Shu T., Lin Y., Wang H., Yang J., Shi Y., Han X., Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β -cells. Biochemical and Biophysical Research Communications 2011 404 1 159 165 2-s2.0-78650890745 10.1016/j.bbrc.2010.11.085
81. Shu T., Zhu Y., Wang H., Lin Y., Ma Z., Han X., Ages decrease insulin synthesis in pancreatic β -cell by repressing pdx-1 protein expression at the post-translational level. PLoS ONE 2011 6 4 2-s2.0-79955134104 10.1371/journal.pone.0018782 e18782
82. McKillop A. M., Abdel-Wahab Y. H. A., Mooney M. H., O'Harte F. P. M., Flatt P. R., Secretion of glycated insulin from pancreatic β -cells in diabetes represents a novel aspect of β -cell dysfunction and glucose toxicity. Diabetes and Metabolism 2002 28 6 3 S61 2-s2.0-12244304179
83. McKillop A. M., Lindsay J. R., Au S., Mahood K. I., O'Harte F. P. M., Flatt P. R., Bell P. M., Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects. Hormone and Metabolic Research 2006 38 2 94 97 2-s2.0-33645721086 10.1055/s-2006-925125
84. Abdel-Wahab Y. H. A., O'Harte F. P. M., Boyd A. C., Barnett C. R., Flatt P. R., Glycation of insulin results in reduced biological activity in mice. Acta Diabetologica 1997 34 4 265 270 2-s2.0-0031449216 10.1007/s005920050086 (Pubitemid 28010556)
85. Boyd A. C., Abdel-Wahab Y. H. A., McKillop A. M., McNulty H., Barnett C. R., O'Harte F. P. M., Flatt P. R., Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. Biochimica et Biophysica Acta 2000 1523 1 128 134 2-s2.0-0034283354 10.1016/S0304-4165(00)00113-6
86. Bonapace I. M., Addeo R., Altucci L., Cicatiello L., Bifulco M., Laezza C., Salzano S., Sica V., Bresciani F., Weisz A., 17 β -Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. Oncogene 1996 12 4 753 763 2-s2.0-0029670707
87. Corman B., Duriez M., Poitevin P., Heudes D., Bruneval P., Tedgui A., Levy B. I., Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 1998 95 3 1301 1306 2-s2.0-0032477913 10.1073/pnas.95.3.1301 (Pubitemid 28124953)
88. Kern T. S., Engerman R. L., Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001 50 7 1636 1642 2-s2.0-0035409354 (Pubitemid 33639605)
89. Monacelli F., Poggi A., Storace D., Durante A., Traverso N., Viviani G. L., Odetti P., Effects of valsartan therapy on protein glycoxidation. Metabolism: Clinical and Experimental 2006 55 12 1619 1624 2-s2.0-33751541642 10.1016/j.metabol.2006.07.024 (Pubitemid 44830135)
90. Odetti P., Pesce C., Traverso N., Menini S., Maineri E. P., Cosso L., Valentini S., Patriarca S., Cottalasso D., Marinari U. M., Pronzato M. A., Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes 2003 52 2 499 505 2-s2.0-0037315164 10.2337/diabetes.52.2.499 (Pubitemid 36173209)
91. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. I., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochemical and Biophysical Research Communications 2010 391 3 1405 1408 2-s2.0-73949118948 10.1016/j.bbrc.2009.12.075
92. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S., Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Hormone and Metabolic Research 2011 43 10 731 734 10.1055/s-0031-1284383
93. Matsui T., Nishino Y., Takeuchi M., Yamagishi S. I., Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacological Research 2011 63 5 383 388 2-s2.0-79955480528 10.1016/j.phrs.2011.02.003
94. Zhan Y., Sun H. L., Chen H., Zhang H., Sun J., Zhang Z., Cai D. H., Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Medical Science Monitor 2012 18 7 BR286 BR291
95. Kimura R., Okouchi M., Fujioka H., Ichiyanagi A., Ryuge F., Mizuno T., Imaeda K., Okayama N., Kamiya Y., Asai K., Joh T., Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009 162 4 1212 1219 2-s2.0-67949112601 10.1016/j.neuroscience.2009.05.025
96. Ishibashi Y., Nishino Y., Matsui T., Takeuchi M., Yamagishi S., Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011 60 9 1271 1277 10.1016/j.metabol.2011.01.010